Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp


WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Pharma GmbH’s U.S. patent number 17/215,785 (‘785 patent), titled “Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device,” which protects a number of innovations relating to the RhodoLED XL lamp.

See the rest here:
Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp

Related Posts